Gene expression profiles reveal homeostatic dynamics during interferon- sub( beta ) therapy in multiple sclerosis

Understanding the mechanisms that sustain the effects of disease modifying drugs in multiple sclerosis (MS) may help refine current therapies and improve our knowledge of disease pathogenesis. By using cDNA microarrays, we investigated gene expression in the peripheral blood mononuclear cells (PBMC)...

Full description

Saved in:
Bibliographic Details
Published in:Autoimmunity (Chur, Switzerland) Switzerland), 2007-01, Vol.40 (1), p.16-22
Main Authors: Annibali, V, Di Giovanni, S, Cannoni, S, Giugni, E, Bomprezzi, R, Mattei, C, Elkahloun, A, Coccia, E M, Alfo, M, Orzi, F, Ristori, G, Salvetti, M
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Understanding the mechanisms that sustain the effects of disease modifying drugs in multiple sclerosis (MS) may help refine current therapies and improve our knowledge of disease pathogenesis. By using cDNA microarrays, we investigated gene expression in the peripheral blood mononuclear cells (PBMC) of 7 MS patients, at baseline (TO) as well as after 1 (T1) and 3 months (T3) of interferon beta-1a (IFN- beta -1a; Rebif super(TM) 44 mu g) therapy. Gene expression changes involved genes of both immunological and non-immunological significance. We validated IL-10 up-regulation, which is in accordance with previous reports, and other novel changes that underscore the capacity of IFN- beta to impair antigen presentation and migration of inflammatory elements into the central nervous system (up-regulation of filamin B and down-regulation of lL-16 and rab7). Overall, gene expression changes became less pronounced after 3 months of therapy, suggesting a homeostatic response to IFN- beta . This may be of use for the design of new treatment schedules.
ISSN:0891-6934
DOI:10.1080/08916930601135241